Lupin launches generic Xarelto
Rivaroxaban tablets are used to reduce the risk of major cardiovascular events in patients with CAD.
Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto.
The medication is used to reduce the risk of major cardiovascular events in patients with coronary artery disease; to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease, including patients after recent lower extremity revascularization due to symptomatic PAD.
[Read more: Lupin receives FDA OK for generic Banzel]
Rivaroxaban tablets 2.5 mg (RLD Xarelto) had a market value of roughly $446 million, per IQVIA January 2025 data.
[Read more: Lupin launches generic Minzoya]